




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 47/40</b>	<b>A1</b>	(11) International Publication Number: <b>WO 98/58677</b> (43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: <b>PCT/EP98/03477</b> (22) International Filing Date: <b>2 June 1998 (02.06.98)</b> (30) Priority Data: <b>9713149.4</b> <b>21 June 1997 (21.06.97)</b> <b>GB</b> (71) Applicant (for GB only): <b>PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</b> (71) Applicant (for all designated States except GB US): <b>PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).</b> (72) Inventor; and (75) Inventor/Applicant (for US only): <b>HARDING, Valerie, Denise [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</b> (74) Agents: <b>HAYLES, James, Richard et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  Published With international search report.
(54) Title: <b>PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE</b>  (57) Abstract  The invention provides a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula (I), wherein R <sup>1a-g</sup> , R <sup>2a-g</sup> and R <sup>3a-g</sup> independently represent OH or O(CH <sub>2</sub> ) <sub>4</sub> SO <sub>3</sub> H; or a pharmaceutically acceptable salt thereof.		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Pharmaceutical formulations containing voriconazole**

This invention relates to a new pharmaceutical formulation of voriconazole with a sulphobutylether  $\beta$ -cyclodextrin.

5

Voriconazole is disclosed in European Patent Application 0440372 (see Example 7). It has the following structure:




and is useful in the treatment of fungal infections. Voriconazole has a low aqueous solubility (0.2mg/ml @ pH 3), and is not stable in water (an inactive enantiomer is formed from recombination of the retro-aldol products of hydrolysis). Thus, development of an aqueous intravenous formulation with a sufficient shelf life is difficult. These problems are magnified by the semi-polar nature of the compound (log D = 1.8) which means that it is not generally solubilised by conventional means such as oils, surfactants or water miscible co-solvents.

15

European Patent Application 0440372 mentions that the compounds disclosed therein may be formulated with cyclodextrin: however, it is now suspected that underivatised or unmetabolised cyclodextrin has toxic effects on the body and so is unsuitable as a pharmaceutical excipient, particularly when administered parenterally.

20

International Patent Application WO 91/11172 discloses sulphoalkylether cyclodextrin derivatives of formula A,




wherein

$n$  is 4, 5 or 6;

$R_{1-9}$  independently represent  $O^-$  or  $O-(C_{2-6} \text{ alkylene})-SO^-$ , provided that at least one of  $R_1$  and  $R_2$  is  $O-(C_{2-6} \text{ alkylene})-SO^-$ ; and  
 $S_{1-9}$  independently represent a pharmaceutically acceptable cation (such as  $H^+$  or  $Na^+$ ).

It has now been found that the solubility of voriconazole in water can be increased by molecular encapsulation with sulphoalkylether cyclodextrin derivatives of the type disclosed in International Patent Application WO 91/11172, particularly when  $n$  is 5 (a  $\beta$ -cyclodextrin derivative) and the cyclodextrin ring is substituted by sulphobutyl groups.

Thus, according to the present invention, there is provided a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula I.



wherein

$R^{1a-g}$ ,  $R^{2a-g}$  and  $R^{3a-g}$  independently represent  $OH$  or  $O(CH_2)_4SO_3H$ ; provided that at least one of  $R^{1a-g}$  represents  $O(CH_2)_4SO_3H$ ;

or a pharmaceutically acceptable salt thereof.

Pharmaceutically acceptable salts of particular interest are salts of the  $\text{O}(\text{CH}_2)_4\text{SO}_3\text{H}$  groups, for example alkali metal salts, such as sodium salts.

5

Preferably, the average number of  $\text{O}(\text{CH}_2)_4\text{SO}_3\text{H}$  groups per molecule of formula I is in the range 6.1-6.9, for example 6.5. This enhances molecular encapsulation resulting in enhanced voriconazole solubility. This effect would not be anticipated because increasing the degree of substitution increases steric hindrance around the cavity of the cyclodextrin and would be expected to reduce complexation efficiency.

10

It is preferred that each  $\text{O}(\text{CH}_2)_4\text{SO}_3\text{H}$  present is in the form of an alkali metal salt (such as the sodium salt). This enhances the affinity of the molecule for voriconazole, which is unexpected because voriconazole is not charged.

15

Preferably, the formulation is for parenteral administration, for example, i.v. administration.

The aqueous stability of the voriconazole-cyclodextrin derivative complex is further enhanced by lyophilisation (freeze-drying). The cyclodextrin derivatives used in formulations according to the invention enable the finished lyophilised product to accommodate high levels of moisture (up to 3.0%) without a detrimental effect on stability. Furthermore, the use of such cyclodextrin derivatives controls and minimises the formation of the inactive enantiomer of voriconazole.

20

25

Generally, in aqueous intravenous and intramuscular formulations according to the invention, the voriconazole will be present at a concentration of from 5 mg/ml to 50 mg/ml, for example 10 mg/ml to 30 mg/ml. The cyclodextrin derivative of formula I will be present in a molar ratio of voriconazole:cyclodextrin derivative of from 1:1 to 1:10, for example 1:2 to 1:7, in particular 1:2 to 1:3. The formulations may be lyophilised (freeze dried) for storage prior to use, and made up with water when required.

30

In the following example, the sulphobutylether  $\beta$ -cyclodextrin has an average sulphobutylether substitution of 6.5 per cyclodextrin molecule, and each sulphobutylether unit is present as its sodium salt.

5 **Example 1**

**i.v. formulation of voriconazole**


<u>Ingredient</u>	<u>Specification</u>	<u>mg/ml</u>
Voriconazole	Pfizer	10.000
10 Sulphobutylether $\beta$ -cyclodextrin	Pfizer	160.000
Water for injections	Ph. Eur.	to 1.000 ml
	Total	1.000 ml

**Method:**

- 15 1. With constant stirring, add the sulphobutylether  $\beta$  cyclodextrin (SBECD) to 80% of the final volume of water for injections, and continue to stir until all the SBECD has dissolved.
2. Add the voriconazole and dissolve with stirring.
3. Make the solution up to volume with water for injections.
- 20 4. Filter the resulting solution through a sterile 0.2 mm nylon filter into a sterile container.
5. Fill 20 ml volumes into sterile freeze drying vials and stopper. Lyophilise.

Claims:

1. A pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula I,



5

wherein

$R^{1a-g}$ ,  $R^{2a-g}$  and  $R^{3a-g}$  independently represent OH or  $O(CH_2)_4SO_3H$ ;

provided that at least one of  $R^{1a-g}$  represents  $O(CH_2)_4SO_3H$ ;

or a pharmaceutically acceptable salt thereof.

- 10 2. A formulation as claimed in claim 1, wherein the average number of  $O(CH_2)_4SO_3H$  groups per molecule of formula I is in the range 6.1-6.9.
3. A formulation as claimed in claim 1 or claim 2, wherein each  $O(CH_2)_4SO_3H$  present is in the form of an alkali metal salt.
4. A formulation as claimed in any one of the preceding claims, which is adapted for  
15 parenteral administration.
5. A formulation as claimed in any one of the preceding claims, wherein the cyclodextrin derivative of formula I is present in a molar ratio of voriconazole:cyclodextrin derivative of from 1:1 to 1:10.
6. A formulation as claimed in any one of the preceding claims, which is a solution in  
20 water.
7. A formulation as claimed in any one of claims 1-5, which has been lyophilised.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03477

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K47/40

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 440 372 A (PFIZER INC.) 7 August 1991 cited in the application see claims; example 7 ---	1-7
A	EP 0 357 241 A (PFIZER LIMITED) 7 March 1990 see claims ---	1-7
A	WO 94 02518 A (THE UNIVERSITY OF KANSAS) 3 February 1994 see claims ---	1-7
A	WO 91 11172 A (THE UNIVERSITY OF KANSAS) 8 August 1991 cited in the application see claims ---	1-7
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 September 1998

Date of mailing of the international search report

24/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03477

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 97 01552 A (PFIZER INC.)  16 January 1997  see claims 1,16-20</p> <p>-----</p>	1-7

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 440372 A	07-08-1991	AP 223 A	27-08-1992
		AU 625188 B	02-07-1992
		AU 7022391 A	05-09-1991
		BG 60032 A	15-07-1993
		CA 2035314 A	03-08-1991
		CN 1053787 A,B	14-08-1991
		CN 1100421 A	22-03-1995
		CS 9100249 A	15-09-1991
		DK 440372 T	28-06-1993
		EG 19750 A	31-01-1996
		ES 2055523 T	16-08-1994
		FI 910508 A	03-08-1991
		FI 971238 A	25-03-1997
		HK 219396 A	03-01-1997
		HU 9500179 A	28-07-1995
		IE 64774 B	06-09-1995
		IL 97045 A	27-11-1995
		IL 110322 A	31-10-1996
		JP 2625584 B	02-07-1997
		JP 4211078 A	03-08-1992
		JP 9208583 A	12-08-1997
		KR 9311039 B	20-11-1993
		LV 10615 A	20-04-1995
		LV 10615 B	20-12-1995
		MX 24363 A	01-09-1993
		NO 176796 B	20-02-1995
		OA 9480 A	15-11-1992
		PL 169332 B	31-07-1996
		PL 169307 B	28-06-1996
		PT 96617 A	15-10-1991
		SK 278215 B	03-04-1996
		RU 2036194 C	27-05-1995
		US 5567817 A	22-10-1996
		US 5773443 A	30-06-1998
		US 5278175 A	11-01-1994
EP 357241 A	07-03-1990	AP 104 A	02-11-1990
		AU 602638 B	18-10-1990
		AU 3893089 A	22-03-1990
		BG 60865 B	31-05-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 357241 A		CN 1040795 A,B	28-03-1990
		CY 1968 A	05-09-1997
		DE 68913105 D	24-03-1994
		DE 68913105 T	26-05-1994
		DK 394589 A	14-02-1990
		EG 19640 A	31-10-1995
		ES 2062009 T	16-12-1994
		FI 893809 A,B,	14-02-1990
		HU 9500436 A	28-09-1995
		IE 61412 B	02-11-1994
		IL 91231 A	26-08-1994
		IL 106262 A	19-01-1996
		JP 2075069 C	25-07-1996
		JP 2104583 A	17-04-1990
		JP 7086100 B	20-09-1995
		JP 2713394 B	16-02-1998
		JP 7173154 A	11-07-1995
		LV 10714 A	20-06-1995
		LV 10714 B	20-12-1995
		MX 17169 A	01-08-1993
		NO 174101 C	16-03-1994
		OA 9126 A	31-10-1991
		PL 162953 B	31-01-1994
		PL 163756 B	29-04-1994
		PT 91440 A,B	08-03-1990
		SU 1836366 A	23-08-1993
		RU 2095358 C	10-11-1997
		US 5364938 A	15-11-1994
		US 5116844 A	26-05-1992
		US 5206364 A	27-04-1993
WO 9402518 A	03-02-1994	US 5376645 A	27-12-1994
		AU 672814 B	17-10-1996
		AU 4779993 A	14-02-1994
		CA 2119154 A	03-02-1994
		EP 0620828 A	26-10-1994
		JP 6511513 T	22-12-1994
WO 9111172 A	08-08-1991	US 5134127 A	28-07-1992
		AT 170742 T	15-09-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9111172 A		AU 646020 B	03-02-1994
		AU 7236491 A	21-08-1991
		CA 2074186 A	24-07-1991
		EP 0512050 A	11-11-1992
		JP 2722277 B	04-03-1998
		JP 5504783 T	22-07-1993
		RU 2099354 C	20-12-1997
		US 5376645 A	27-12-1994
WO 9701552 A	16-01-1997	AU 6301096 A	30-01-1997
		EP 0835252 A	15-04-1998
		JP 10506652 T	30-06-1998
		NO 976047 A	25-02-1998
		PL 324336 A	25-05-1998